METABOLIC / DIRECT CATALOG PRICING
Tirzepatide
Tirzepatide is an acylated peptide engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
- Format
- Lyophilized research vial
- Listed formats
- 7
- Available now
- 7
- Catalog class
- Metabolic
Choose a listed format
- 10 mg$34.00 · AvailableSelect format
- 15 mg$48.00 · AvailableSelect format
- 20 mg$55.00 · AvailableSelect format
- 30 mg$60.00 · AvailableSelect format
- 40 mg$73.00 · AvailableSelect format
- 55 mg$78.00 · AvailableSelect format
- 60 mg$68.00 · AvailableSelect format
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
Tirzepatide is an acylated peptide engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
The metabolic classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Metabolic
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- 7 formats currently orderable
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
Tirzepatide is an acylated peptide engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
- Research covered
- Researchers evaluated tirzepatide in randomized phase 2 and phase 3 trials in adults with type 2 diabetes, including a 40-week active-comparator study.
- Important limit
- Results from the named pharmaceutical compound do not verify the identity, purity, formulation, or equivalence of a separately sold research vial.
- Authoritative sources
FACTUAL FAQ
Tirzepatide catalog questions
What formats are currently listed?
10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 55 mg, 60 mg. Current price and stock state appear above.
What did researchers study?
Researchers evaluated tirzepatide in randomized phase 2 and phase 3 trials in adults with type 2 diabetes, including a 40-week active-comparator study.
What is the most important evidence limit?
Results from the named pharmaceutical compound do not verify the identity, purity, formulation, or equivalence of a separately sold research vial.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →